COVID-19*

Welcome to BioNTech’s COVID-19 information portal

*This website is intended for a global audience

At BioNTech, we are humbled to contribute to the worldwide efforts to address the global COVID-19 pandemic. Within less than a year, we were able to develop our COVID-19 mRNA vaccine following highly scientific and ethical standards, which became the first mRNA drug approved for human use and the fastest vaccine developed against a new pathogen in the history of medicine.

Our portal provides information on COVID-19, our mRNA technology and Project Lightspeed, our development program for our mRNA based COVID-19 vaccine. If you are a healthcare professional (HCP), you may access our HCP hub, which includes scientific background information on SARS-CoV-2, medical information on our COVID-19 vaccine and our development program. 

COVID-19 disease

mRNA vaccines

Project Lightspeed

HCP hub

Frequently asked questions

Here we answer questions about our COVID-19 mRNA vaccine und mRNA technology

To address a global challenge like COVID-19, we have undertaken a worldwide effort to develop a well-tolerated and effective vaccine as quickly as science and cutting-edge technology will allow.  Despite the damage caused by the virus, I have been inspired each day by the spirit of collaboration and scientific discovery.

Prof. Ugur Sahin, M.D., Chief Executive Officer

Our collaborations to accelerate global COVID-19 vaccine development: Pfizer and Fosun Pharma

The collaboration with Pfizer is built on the 2018 agreement to jointly develop an mRNA-based influenza vaccine. It aimed to rapidly advance multiple COVID-19 vaccine candidates into human clinical testing based on BioNTech’s proprietary mRNA vaccine platforms, with the objective of ensuring rapid worldwide access to the vaccine. The collaboration leverages Pfizer’s broad expertise in vaccine research and development, regulatory capabilities and global manufacturing and distribution network. During the clinical development stage, BioNTech and its partners provided clinical supply of the vaccine from its GMP-certified mRNA manufacturing facilities in Europe. BioNTech and Pfizer worked together to scale-up manufacturing capacity at risk to provide worldwide supply in response to the pandemic. By the end of 2021, BioNTech and Pfizer have delivered approximately 3 billion doses of the BioNTech-Pfizer COVID-19 Vaccine to more than 160 countries and regions and are planning to deliver up to 4 billion doses in 2022.

As part of our strategic collaboration announced in March 2020, BioNTech and Fosun Pharma are jointly conducting clinical trials for our COVID-19 mRNA vaccine in China, leveraging BioNTech’s proprietary mRNA vaccine technology and Fosun Pharma’s clinical development and commercialization capabilities in the Greater China market. Fosun Pharma will commercialize the COVID-19 vaccine in Greater China upon regulatory approval on the Chinese Mainland and is supplying the vaccine under Emergency Use Authorization in Hong Kong, Macau and Taiwan.

Read also